GO:0006924 activation-induced cell death of T cells: Apoptotic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006924 describes activation-induced cell death (AICD), a T cell apoptotic process that occurs towards the end of the expansion phase after initial antigen-driven activation and is triggered by T cell receptor stimulation and TNF receptor family signals such as Fas/FasL and TNF/p55/p75.
• AICD is a key peripheral tolerance mechanism that eliminates chronically activated T cells and prevents excessive immune expansion.
• The Fas/FasL system is the best-characterized effector pathway of AICD, but TNF and its p55/p75 receptors also contribute to the process.
• Dysregulated AICD is linked to autoimmunity, persistent infections, and tumor immune escape, making it a target for therapeutic modulation.
• AICD is relevant to CAR-T cell therapy, where it can limit persistence and antitumor efficacy.
• Studying AICD requires integrated methods including flow cytometry, CRISPR knockout models, transcriptomics, and functional apoptosis assays.
Description
Activation-induced cell death (AICD) of T cells, formally annotated as GO:0006924, is a biological process in which mature T cells undergo apoptosis towards the end of the expansion phase following initial activation by antigen. This process is triggered by T cell receptor (TCR) stimulation and signals transmitted via surface-expressed members of the TNF receptor family, including Fas ligand, Fas, TNF, and the p55 and p75 TNF receptors. AICD is a fundamental mechanism of peripheral immune tolerance that removes chronically activated T cells and prevents uncontrolled immune responses. Because AICD balances T cell expansion and contraction, its dysregulation has broad implications for human disease. Defective AICD can permit survival of autoreactive T cells and contribute to autoimmunity, whereas excessive AICD can impair pathogen clearance and antitumor immunity. In cancer, tumor-driven signals can sensitize tumor-specific T cells to AICD, promoting immune escape. In CAR-T cell therapy, AICD limits the persistence and efficacy of engineered T cells, making it a barrier to durable responses. Understanding the molecular regulation of AICD is therefore essential for immunology, oncology, and cell therapy research. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links, and experimental approaches used to study GO:0006924.
activation-induced cell death of T cells At A Glance
| GO ID | GO:0006924 |
|---|---|
| GO term | activation-induced cell death of T cells |
| Ontology | biological_process |
| Synonym | AICD; activated T cell apoptosis; activation-induced cell death of T lymphocytes; antigen-driven apoptosis |
| Major function | Apoptotic elimination of chronically activated mature T cells to maintain peripheral tolerance and immune homeostasis |
| Trigger | T cell receptor stimulation and TNF receptor family signals including Fas/FasL and TNF/p55/p75 |
| Timing | Towards the end of the expansion phase after initial antigen-driven activation |
| Cell type | Mature T lymphocytes |
| Disease relevance | Autoimmunity, tumor immune escape, CAR-T cell therapy limitations, persistent infections |
What Is GO:0006924?
GO:0006924, activation-induced cell death of T cells, is defined as a T cell apoptotic process that occurs towards the end of the expansion phase following the initial activation of mature T cells by antigen. It is triggered by T cell receptor stimulation and by signals transmitted through various surface-expressed members of the TNF receptor family, such as Fas ligand, Fas, TNF, and the p55 and p75 TNF receptors. In simpler terms, it is the programmed self-destruction of activated T cells that helps terminate an immune response after the expansion phase.
Why Is activation-induced cell death of T cells Important in Cell Biology?
AICD is important because it serves as a built-in brake on T cell expansion, preventing excessive immune activation while shaping the repertoire of surviving T cells. Its dysregulation contributes to autoimmune pathology when autoreactive T cells escape deletion, and to immune evasion when tumor-specific T cells are prematurely eliminated. In adoptive cell therapy, AICD limits CAR-T cell persistence and antitumor activity, making it a target for engineering more durable T cell products. Thus, GO:0006924 sits at the intersection of basic immunology, autoimmunity, cancer immunology, and cell therapy development.
• Maintains peripheral tolerance by deleting chronically activated T cells.
• Prevents uncontrolled T cell expansion and immunopathology.
• Defective AICD is associated with autoimmunity and survival of autoreactive T cells.
• Tumor-driven signals can sensitize tumor-specific T cells to AICD, promoting immune escape.
• AICD limits CAR-T cell persistence and efficacy in cancer therapy.
• Fas/FasL and TNF receptor signaling are central to AICD execution.
• Hypoxia and metabolic signals such as HIF1α-regulated glycolysis can promote AICD.
• AICD is a model process for studying apoptosis, TCR signaling, and immune contraction.
• Modulating AICD is a potential strategy to enhance vaccine and immunotherapy responses.
• AICD research informs biomarkers and interventions for autoimmune and infectious diseases.
What Happens During activation-induced cell death of T cells?
T cell activation and expansion
In simple terms: T cells first get switched on by antigen and multiply.
AICD begins after mature T cells are activated by antigen through the T cell receptor, leading to clonal expansion. During this phase, T cells proliferate and acquire sensitivity to death receptor signals. The process occurs towards the end of the expansion phase, distinguishing AICD from other forms of T cell death.
Death receptor upregulation
In simple terms: Activated T cells start displaying death receptors on their surface.
Following activation, T cells upregulate surface-expressed members of the TNF receptor family, including Fas (CD95) and TNF receptors p55 and p75. Fas ligand (FasL) expression is also induced, enabling autocrine or paracrine death signaling. The regulation of FasL expression is a critical checkpoint in AICD.
TCR restimulation and death signaling
In simple terms: A second trigger through the T cell receptor pushes the cells toward death.
T cell receptor stimulation provides the trigger for AICD, often in the context of repeated or persistent antigen exposure. This restimulation leads to death receptor engagement and initiation of apoptotic signaling. Signals transmitted via Fas/FasL and TNF/p55/p75 converge on caspase activation.
Apoptotic execution
In simple terms: The cell dismantles itself through programmed cell death.
Engagement of death receptors activates caspase cascades that execute apoptosis, leading to DNA fragmentation and cell death. This apoptotic process eliminates activated T cells and contributes to the contraction of the immune response. The balance between pro-survival and pro-apoptotic signals determines whether a T cell undergoes AICD.
Metabolic and microenvironmental modulation
In simple terms: The environment and metabolism can make T cells more or less likely to die.
Hypoxia and metabolic reprogramming can influence AICD. HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells. Tumor-derived factors such as mutant KRAS-activated circATXN7 can sensitize tumor-specific T cells to AICD, fostering immunoescape. These findings highlight that AICD is modulated by both intrinsic metabolism and extrinsic tumor signals.
Key Genes Involved in GO:0006924 activation-induced cell death of T cells
The following genes and proteins are central to the regulation and execution of activation-induced cell death of T cells (GO:0006924), based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FAS | Death receptor mediating AICD signaling | Target for studying apoptosis and autoimmunity |
| FASLG | Ligand for FAS; induces AICD | Regulation of FasL expression is a key AICD checkpoint |
| TNF | Cytokine that can trigger AICD via TNF receptors | Involved in TNF receptor family signaling in AICD |
| TNFRSF1A | p55 TNF receptor; transmits death/survival signals | Contributes to AICD triggered by TNF |
| TNFRSF1B | p75 TNF receptor; modulates TNF signaling | Participates in AICD-associated TNF receptor signaling |
| CASP3 | Executioner caspase in apoptosis | Effector of AICD-related apoptosis |
| CASP8 | Initiator caspase downstream of death receptors | Mediates Fas/TNF receptor-induced apoptosis |
| HIF1A | Hypoxia-inducible factor; regulates glycolysis | Promotes AICD and IFN-γ induction in hypoxic T cells |
| KRAS | Oncogene; mutant KRAS activates circATXN7 | Links tumor signaling to T cell AICD sensitivity |
| CIRC_ATXN7 | Circular RNA activated by mutant KRAS | Sensitizes tumor-specific T cells to AICD |
| IFNG | Cytokine induced alongside AICD in hypoxic T cells | Readout of T cell activation and AICD |
| CD95 | Alternative name for FAS death receptor | Core AICD receptor |
| CD95L | Alternative name for FAS ligand | Core AICD ligand |
| BCL2 | Anti-apoptotic regulator | Modulates susceptibility to AICD |
| BCL2L1 | Anti-apoptotic regulator (Bcl-xL) | Influences T cell survival during AICD |
| MCL1 | Anti-apoptotic regulator | Contributes to T cell survival balance |
| NFKB1 | Transcription factor regulating survival and FasL | Modulates AICD-associated gene expression |
How Is activation-induced cell death of T cells Regulated?
AICD is regulated at multiple levels, including death receptor expression, caspase activation, and metabolic signaling. FasL expression is a critical regulatory node, and its induction is controlled by TCR and co-stimulatory signals. The balance between pro-apoptotic and anti-apoptotic Bcl-2 family proteins influences whether activated T cells survive or die. Hypoxia and HIF1α-regulated glycolysis can promote AICD, linking metabolic state to cell death. Tumor-derived signals, such as mutant KRAS-activated circATXN7, can sensitize T cells to AICD, demonstrating extrinsic regulation in the tumor microenvironment. These layers of regulation ensure that AICD occurs at the appropriate time to contract immune responses.
activation-induced cell death of T cells and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FAS | Autoimmunity and lymphoproliferation | Fas knockout mouse or CRISPR KO T cells |
| FASLG | Autoimmune disease and immune dysregulation | FasL knockout or overexpression models |
| KRAS | Tumor immune escape | Mutant KRAS tumor models with T cell co-culture |
| HIF1A | Hypoxic tumor microenvironment and T cell dysfunction | HIF1A knockout or overexpression in T cells under hypoxia |
| CASP8 | Apoptosis defects and immunodeficiency | Casp8 knockout T cell lines |
Autoimmunity
Defective AICD can allow autoreactive T cells to persist, contributing to autoimmune diseases. Impaired deletion of activated T cells may lead to sustained immune attack on self tissues. Understanding AICD mechanisms is therefore relevant to autoimmune disease pathogenesis and therapy.
Cancer and tumor immune escape
Tumors can sensitize tumor-specific T cells to AICD, reducing antitumor immunity. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death. This highlights AICD as a barrier to effective cancer immunotherapy.
CAR-T cell therapy
AICD limits the persistence and efficacy of CAR-T cells in cancer therapy. Strategies to modulate AICD may improve CAR-T cell durability and clinical outcomes.
Infections and immune contraction
AICD contributes to the contraction of T cell responses after infection, which is necessary to restore immune homeostasis. Dysregulated AICD may affect pathogen clearance and memory T cell formation.
From activation-induced cell death of T cells-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate AICD? | CRISPR knockout of gene X in primary T cells or Jurkat cells followed by TCR restimulation |
| Does a point mutation in FAS alter AICD? | Point-mutation knock-in of FAS variants in T cell lines |
| Does overexpression of anti-apoptotic gene Y block AICD? | Overexpression of BCL2 or BCL2L1 in T cells |
| Does tagged protein X localize to death receptor complexes? | Knock-in of epitope-tagged FAS or CASP8 |
| Does metabolic gene Z modulate AICD under hypoxia? | HIF1A knockout or overexpression in T cells cultured under hypoxia |
| Does tumor-derived circRNA affect T cell AICD? | Co-culture of tumor cells expressing circATXN7 with T cells |
How to Study the activation-induced cell death of T cells Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry (Annexin V/PI) | Apoptotic and dead cell frequencies | Quantifying AICD after TCR restimulation |
| RNA-seq | Transcriptional changes during AICD | Identifying death receptor and metabolic gene expression |
| Proteomics | Protein expression and cleavage events | Detecting caspase activation and death receptor complexes |
| Caspase activity assay | Enzymatic activity of caspases | Confirming apoptotic execution in AICD |
| CRISPR knockout screen | Gene requirement for AICD | Discovering novel AICD regulators |
| Co-culture assays | T cell death induced by tumor or antigen-presenting cells | Modeling tumor immune escape via AICD |
| Hypoxia chamber experiments | AICD under low oxygen | Studying HIF1α-regulated glycolysis in AICD |
| CAR-T cell assays | AICD in engineered T cells | Improving CAR-T persistence |
Flow cytometry and apoptosis assays
Flow cytometry with Annexin V and propidium iodide staining is widely used to quantify AICD in T cell populations after TCR restimulation. This method measures phosphatidylserine exposure and membrane integrity, providing a direct readout of apoptosis.
Transcriptomics and RNA-seq
RNA sequencing can identify gene expression changes during AICD, including upregulation of FAS, FASLG, and TNF receptor family genes. Transcriptomic profiling of hypoxic T cells has revealed HIF1α-dependent metabolic and AICD-related signatures.
Proteomics and caspase activity assays
Proteomic approaches and caspase activity assays measure the activation of apoptotic executioners such as CASP3 and CASP8. These methods help define the molecular cascade downstream of death receptor engagement.
CRISPR-based functional screens
CRISPR knockout screens can identify genes that regulate AICD sensitivity in T cells. Such screens are valuable for discovering novel modulators of AICD and potential therapeutic targets.
How CRISPR Can Be Used to Study GO:0006924 activation-induced cell death of T cells
Knockout
CRISPR knockout of candidate genes such as FAS, FASLG, or CASP8 in T cell lines or primary T cells can determine whether they are required for AICD. Loss-of-function models help establish causal roles in apoptotic execution and immune contraction.
Point Mutation
Point-mutation knock-in can model disease-associated variants in AICD-related genes, such as FAS mutations linked to autoimmunity. These models allow precise testing of how single amino acid changes alter death receptor signaling.
Knock-in
Knock-in of epitope tags or reporter genes into endogenous loci such as FAS or CASP8 enables tracking of protein localization and expression during AICD. Tagged knock-in models are useful for imaging and proteomic studies of death receptor complexes.
Overexpression
Overexpression of anti-apoptotic genes like BCL2 or BCL2L1 can protect T cells from AICD, while overexpression of pro-apoptotic factors can sensitize them. Such models help dissect the balance of survival and death signals in AICD.
How EDITGENE Supports activation-induced cell death of T cells Research
Researchers studying activation-induced cell death of T cells-related genes often need to determine whether a candidate gene is causally involved in AICD or merely correlated with apoptosis. CRISPR-based models provide a rigorous way to test gene function in this process, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for activation-induced cell death of T cells research.
Frequently Asked Questions About activation-induced cell death of T cells
What is activation-induced cell death of T cells?
It is a T cell apoptotic process that occurs towards the end of the expansion phase after initial activation by antigen, triggered by T cell receptor stimulation and TNF receptor family signals such as Fas/FasL and TNF.
What is GO:0006924?
GO:0006924 is the Gene Ontology identifier for activation-induced cell death of T cells, a biological process describing apoptosis of activated mature T cells.
What genes are involved in activation-induced cell death of T cells?
Key genes include FAS, FASLG, TNF, TNFRSF1A, TNFRSF1B, CASP3, CASP8, and regulators such as BCL2 family members.
What triggers activation-induced cell death?
T cell receptor stimulation and signals through TNF receptor family members such as Fas ligand, Fas, and TNF receptors p55 and p75 trigger AICD.
Why is AICD important for immune tolerance?
AICD eliminates chronically activated T cells, preventing excessive immune responses and maintaining peripheral tolerance.
How is AICD related to autoimmunity?
Defective AICD can allow autoreactive T cells to survive, contributing to autoimmune disease.
How does AICD affect CAR-T cell therapy?
AICD limits CAR-T cell persistence and efficacy, making it a target for engineering more durable T cells.
Can tumors exploit AICD to escape immunity?
Yes, tumor-derived signals such as mutant KRAS-activated circATXN7 can sensitize tumor-specific T cells to AICD, promoting immune escape.
What methods are used to study AICD?
Flow cytometry, RNA-seq, proteomics, caspase assays, and CRISPR screens are commonly used to study AICD.
How can CRISPR help study activation-induced cell death?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of genes in AICD pathways.
Conclusion
GO:0006924, activation-induced cell death of T cells, is a central biological process that contracts T cell responses after antigen-driven expansion. Its execution depends on TCR stimulation and TNF receptor family signals, particularly Fas/FasL and TNF pathways. Dysregulated AICD contributes to autoimmunity, tumor immune escape, and CAR-T cell limitations. Continued research using CRISPR models, transcriptomics, and functional assays will clarify how AICD can be modulated for therapeutic benefit.
References
- 1. Green DR et al.. 2003. Activation-induced cell death in T cells.. Immunol Rev 193:70-81 PMID: 12752672
- 2. Shen H et al.. 2024. HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells.. Nat Commun 15(1):9394 PMID: 39477954
- 3. Zhou C et al.. 2024. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death.. Nat Commun 15(1):499 PMID: 38216551
- 4. Zhang J et al.. 2004. Activation-induced cell death in T cells and autoimmunity.. Cell Mol Immunol 1(3):186-92 PMID: 16219166
- 5. Janssen O et al.. 2000. Regulation of activation-induced cell death of mature T-lymphocyte populations.. Cell Tissue Res 301(1):85-99 PMID: 10928283
- 6. Russell JH. 1995. Activation-induced death of mature T cells in the regulation of immune responses.. Curr Opin Immunol 7(3):382-8 PMID: 7546404
- 7. Arakaki R et al.. 2014. Mechanism of activation-induced cell death of T cells and regulation of FasL expression.. Crit Rev Immunol 34(4):301-14 PMID: 24941158
- 8. Huan T et al.. 2022. Activation-induced cell death in CAR-T cell therapy.. Hum Cell 35(2):441-447 PMID: 35032297
